source
- Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer winGermany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.
- Immunology Society Split Over California’s $8.4 B Proposition 38 Funding MeasureInternal emails obtained by STAT reveal a sharp split within the American Association of Immunologists over California’s Proposition 38, a ballot measure that would direct $8.4 billion of taxpayer…